1
|
Dos Santos DR, Fiais GA, Oliveira HA, Ribas TB, Souza RO, Tsosura TVS, Matsushita DH, Ervolino E, Dornelles RCM, Nakamune ACDMS, Chaves-Neto AH. Assessment of redox state and biochemical parameters of salivary glands in rats treated with anti-obesity drug sibutramine hydrochloride. Clin Oral Investig 2022; 26:5833-5846. [PMID: 35556176 DOI: 10.1007/s00784-022-04539-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2021] [Accepted: 05/04/2022] [Indexed: 11/03/2022]
Abstract
OBJECTIVES To investigate the effects of anti-obesity drug sibutramine hydrochloride (SB) on redox state and biochemical parameters in the salivary glands. MATERIALS AND METHODS Adult male Wistar rats were randomly divided into the following groups (n = 8 per group): control rats treated with vehicle (C) and rats treated with SB (10 mg/kg/day) by intragastric gavage for 28 days. The parotid (PG) and submandibular (SMG) glands were processed using histomorphometric analysis, and total protein, amylase, mucin, and oxidative damage to lipids were determined by measuring the formation of thiobarbituric acid reactive substances (TBARS), total antioxidant capacity (TAC), uric acid (UA), total glutathione (tGSH), superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx), and AKT phosphorylation. RESULTS SB decreased the acinar area, and increased the stromal area in PG, while no effect on the morphometric parameters was observed in SMG. SB also increased oxidative damage to lipids (TBARs). The SB group showed lower total protein, amylase, TAC, UA, tGSH, SOD, CAT, and GPx than the C group in PG, while in SMG, SB decreased total protein, mucin, tGSH, SOD, CAT, and GPx. However, increased AKT phosphorylation observed in both salivary glands suggests that SB exerts low-intensity oxidative stress. CONCLUSIONS SB impaired enzymatic and non-enzymatic antioxidant defenses in the salivary glands of rats. CLINICAL RELEVANCE Chronic treatment with SB could mitigate salivary gland dysfunction due to disturbance of redox state.
Collapse
Affiliation(s)
- Damáris Raissa Dos Santos
- Department of Basic Sciences, School of Dentistry of Araçatuba- UNESP - Universidade Estadual Paulista, Rodovia Marechal Rondon, km 527/528, Aracatuba, São Paulo, CEP 16018-805, Brazil.,Programa de Pós-Graduação Multicêntrico Em Ciências Fisiológicas-SBFIs, Department of Basic Sciences, School of Dentistry of Araçatuba- UNESP - Universidade Estadual Paulista, Aracatuba, São Paulo, Brazil
| | - Gabriela Alice Fiais
- Department of Basic Sciences, School of Dentistry of Araçatuba- UNESP - Universidade Estadual Paulista, Rodovia Marechal Rondon, km 527/528, Aracatuba, São Paulo, CEP 16018-805, Brazil.,Programa de Pós-Graduação Multicêntrico Em Ciências Fisiológicas-SBFIs, Department of Basic Sciences, School of Dentistry of Araçatuba- UNESP - Universidade Estadual Paulista, Aracatuba, São Paulo, Brazil
| | - Henrique Arnaldo Oliveira
- Department of Basic Sciences, School of Dentistry of Araçatuba- UNESP - Universidade Estadual Paulista, Rodovia Marechal Rondon, km 527/528, Aracatuba, São Paulo, CEP 16018-805, Brazil
| | - Tayná Buffulin Ribas
- Department of Basic Sciences, School of Dentistry of Araçatuba- UNESP - Universidade Estadual Paulista, Rodovia Marechal Rondon, km 527/528, Aracatuba, São Paulo, CEP 16018-805, Brazil
| | - Rayne Oliveira Souza
- Department of Basic Sciences, School of Dentistry of Araçatuba- UNESP - Universidade Estadual Paulista, Rodovia Marechal Rondon, km 527/528, Aracatuba, São Paulo, CEP 16018-805, Brazil
| | - Thaís Verônica Saori Tsosura
- Department of Basic Sciences, School of Dentistry of Araçatuba- UNESP - Universidade Estadual Paulista, Rodovia Marechal Rondon, km 527/528, Aracatuba, São Paulo, CEP 16018-805, Brazil.,Programa de Pós-Graduação Multicêntrico Em Ciências Fisiológicas-SBFIs, Department of Basic Sciences, School of Dentistry of Araçatuba- UNESP - Universidade Estadual Paulista, Aracatuba, São Paulo, Brazil
| | - Doris Hissako Matsushita
- Department of Basic Sciences, School of Dentistry of Araçatuba- UNESP - Universidade Estadual Paulista, Rodovia Marechal Rondon, km 527/528, Aracatuba, São Paulo, CEP 16018-805, Brazil.,Programa de Pós-Graduação Multicêntrico Em Ciências Fisiológicas-SBFIs, Department of Basic Sciences, School of Dentistry of Araçatuba- UNESP - Universidade Estadual Paulista, Aracatuba, São Paulo, Brazil
| | - Edilson Ervolino
- Department of Basic Sciences, School of Dentistry of Araçatuba- UNESP - Universidade Estadual Paulista, Rodovia Marechal Rondon, km 527/528, Aracatuba, São Paulo, CEP 16018-805, Brazil
| | - Rita Cássia Menegati Dornelles
- Department of Basic Sciences, School of Dentistry of Araçatuba- UNESP - Universidade Estadual Paulista, Rodovia Marechal Rondon, km 527/528, Aracatuba, São Paulo, CEP 16018-805, Brazil.,Programa de Pós-Graduação Multicêntrico Em Ciências Fisiológicas-SBFIs, Department of Basic Sciences, School of Dentistry of Araçatuba- UNESP - Universidade Estadual Paulista, Aracatuba, São Paulo, Brazil
| | - Ana Cláudia de Melo Stevanato Nakamune
- Department of Basic Sciences, School of Dentistry of Araçatuba- UNESP - Universidade Estadual Paulista, Rodovia Marechal Rondon, km 527/528, Aracatuba, São Paulo, CEP 16018-805, Brazil.,Programa de Pós-Graduação Multicêntrico Em Ciências Fisiológicas-SBFIs, Department of Basic Sciences, School of Dentistry of Araçatuba- UNESP - Universidade Estadual Paulista, Aracatuba, São Paulo, Brazil
| | - Antonio Hernandes Chaves-Neto
- Department of Basic Sciences, School of Dentistry of Araçatuba- UNESP - Universidade Estadual Paulista, Rodovia Marechal Rondon, km 527/528, Aracatuba, São Paulo, CEP 16018-805, Brazil. .,Programa de Pós-Graduação Multicêntrico Em Ciências Fisiológicas-SBFIs, Department of Basic Sciences, School of Dentistry of Araçatuba- UNESP - Universidade Estadual Paulista, Aracatuba, São Paulo, Brazil.
| |
Collapse
|
2
|
Dudek M, Marcinkowska M, Bucki A, Olczyk A, Kołaczkowski M. Idalopirdine - a small molecule antagonist of 5-HT6 with therapeutic potential against obesity. Metab Brain Dis 2015; 30:1487-94. [PMID: 26419385 PMCID: PMC4642593 DOI: 10.1007/s11011-015-9736-3] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/02/2015] [Accepted: 09/17/2015] [Indexed: 11/14/2022]
Abstract
5HT6 receptor antagonists offer the potential for safe and effective drugs against obesity, because they can reduce weight without causing serious side effects in the cardiovascular system. Also, their anorexic effect is associated with reduced food intake via an enhancement of satiety. In the present study we investigated the anorexic effect of idalopirdine (LuAE58054) in a model of obesity induced by high-fat diet. To induce obesity in rats, the animals were treated with feed with a fat content of 40 %. Body weight was controlled and the amount of food and water consumed was determined. The influence of the test compound on the lipid profile and glucose level was measured, as well as locomotor activity in home cages on the 20th day of the treatment. LuAE58054, at 5 mg kg(-1)/day i.p., was significantly anorectic in this model of obesity. Animals treated with LuAE58054 weighed 8 and 9.2 % less than the control obese animals on the 12th and 21st days, respectively. It significantly reduced food intake and the amount of peritoneal fat in animals, and reduced the level of triglycerides in plasma. LuAE58054 did not have a statistically significant effect on the spontaneous activity of diet-induced obese rats. The present study clearly demonstrates the effectiveness of LuAE58054 in reducing body weight. This compound is in phase III of clinical trials for the treatment of cognitive deficits associated with Alzheimer's disease and schizophrenia. It is a 5HT6 receptor antagonist and is, therefore, free of those unacceptable side effects that preclude chronic use of anti-obesity drugs with other mechanisms of action. The search for an effective and safe anti-obesity drug is essential for an increasingly obese population; therefore, the anorectic action of LuAE58054 is important and there is a need for more research in this direction.
Collapse
Affiliation(s)
- Magdalena Dudek
- Department of Pharmacodynamics, Jagiellonian University, Collegium Medicum, 9 Medyczna Street, PL 30-688, Kraków, Poland.
| | - Monika Marcinkowska
- Chair of Pharmaceutical Chemistry, Faculty of Pharmacy, Jagiellonian University, Collegium Medicum, Medyczna 9, 30-688, Kraków, Poland
| | - Adam Bucki
- Chair of Pharmaceutical Chemistry, Faculty of Pharmacy, Jagiellonian University, Collegium Medicum, Medyczna 9, 30-688, Kraków, Poland
| | - Adrian Olczyk
- Institute of Automatic Control, Silesian University of Technology, Gliwice, Poland
| | - Marcin Kołaczkowski
- Chair of Pharmaceutical Chemistry, Faculty of Pharmacy, Jagiellonian University, Collegium Medicum, Medyczna 9, 30-688, Kraków, Poland
| |
Collapse
|
3
|
Pola A, Sadananthan SA, Gopalan V, Tan MLS, Keong TY, Zhou Z, Ishino S, Nakano Y, Watanabe M, Horiguchi T, Nishimoto T, Zhu B, Velan SS. Investigation of Fat Metabolism during Antiobesity Interventions by Magnetic Resonance Imaging and Spectroscopy. MAGNETIC RESONANCE INSIGHTS 2014; 7:33-40. [PMID: 25574137 PMCID: PMC4251539 DOI: 10.4137/mri.s19362] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/13/2014] [Revised: 10/17/2014] [Accepted: 10/28/2014] [Indexed: 12/20/2022]
Abstract
The focus of current treatments for obesity is to reduce the body weight or visceral fat, which requires longer duration to show effect. In this study, we investigated the short-term changes in fat metabolism in liver, abdomen, and skeletal muscle during antiobesity interventions including Sibutra mine treatment and diet restriction in obese rats using magnetic resonance imaging, magnetic resonance spectroscopy, and blood chemistry. Sibutramine is an antiobesity drug that results in weight loss by increasing satiety and energy expenditure. The Sibutramine-treated rats showed reduction of liver fat and intramyocellular lipids on day 3. The triglycerides (TG) decreased on day 1 and 3 compared to baseline (day 0). The early response/nonresponse in different fat depots will permit optimization of treatment for better clinical outcome rather than staying with a drug for longer periods.
Collapse
Affiliation(s)
- Arunima Pola
- Laboratory of Molecular Imaging, Singapore Bioimaging Consortium, A*STAR, Singapore
| | | | - Venkatesh Gopalan
- Laboratory of Molecular Imaging, Singapore Bioimaging Consortium, A*STAR, Singapore
| | | | - Terry Yew Keong
- Laboratory of Molecular Imaging, Singapore Bioimaging Consortium, A*STAR, Singapore
| | | | - Seigo Ishino
- Takeda Pharmaceutical Company Limited, Tokyo, Japan
| | | | | | | | | | - Bin Zhu
- Takeda Singapore Pte. Ltd., Singapore
| | - S Sendhil Velan
- Laboratory of Molecular Imaging, Singapore Bioimaging Consortium, A*STAR, Singapore
- Singapore Institute for Clinical Sciences, A*STAR, Singapore
- Clinical Imaging Research Centre, NUS-A*STAR, Singapore
| |
Collapse
|
4
|
Künnecke B, Verry P, Bénardeau A, von Kienlin M. Quantitative Body Composition Analysis in Awake Mice and Rats by Magnetic Resonance Relaxometry. ACTA ACUST UNITED AC 2012; 12:1604-15. [PMID: 15536224 DOI: 10.1038/oby.2004.200] [Citation(s) in RCA: 47] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
OBJECTIVE Magnetic resonance (MR) relaxometry has recently been introduced for noninvasive body composition analysis in awake mice. The purpose of the present study was to extend the method to rats and to introduce calibration procedures that render MR relaxometry fully quantitative. RESEARCH METHODS AND PROCEDURES Proton T(2) MR relaxometry at 4.7 Tesla was used for body composition analyses in 700 awake mice and 400 rats of different strains and conditions. Relaxograms calculated from the signal decays observed with multi-spin-echo acquisition provided well-separated contributions of tissue water and fat. Analysis of fat composition was carried out in vivo using (13)C-MR spectroscopy. Evolution of body composition in rats was assessed during drug treatment. RESULTS MR relaxometry for noninvasive body composition analysis in laboratory rodents was implemented on a standard MR scanner, and a throughput of >30 animals per hour was achieved. Excellent linearity and reproducibility with coefficients of variance as low as 2.5% and 1.7% were obtained in mice and rats, respectively. The lean mass-to-water ratio (mice, 1.35 +/- 0.03; rats, 1.39 +/- 0.04) and the proton density of fat (mice, 8.1 +/- 0.2; rats, 8.9 +/- 0.2 g/mol) were determined from cross-sectional data. Fat composition analysis by (13)C-MR spectroscopy corroborated these findings and yielded information on the average acyl chain length (16.3 +/- 1.6) and contributions of saturated (27 +/- 3%), monounsaturated (22 +/- 2%), and polyunsaturated (51 +/- 3%) fatty acids. Longitudinal assessments in rats treated with sibutramine and dexfenfluramine showed dose-related changes in body composition. DISCUSSION T(2) MR relaxometry backed by solid calibration provides a powerful means for rapid quantitative body composition analysis in awake mice and rats that is suitable for serial investigations in pharmaceutical research.
Collapse
Affiliation(s)
- Basil Künnecke
- Magnetic Resonance Imaging and Spectroscopy, PRBD-M, Building 68/05A, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, CH-4070 Basel, Switzerland.
| | | | | | | |
Collapse
|
5
|
Abstract
The central nervous system (CNS), generally accepted to regulate energy homeostasis, has been implicated in the metabolic perturbations that either cause or are associated with obesity. Normally, the CNS receives hormonal, metabolic, and neuronal input to assure adequate energy levels and maintain stable energy homeostasis. Recent evidence also supports that the CNS uses these same inputs to regulate glucose homeostasis and this aspect of CNS regulation also becomes impaired in the face of dietary-induced obesity. This review focuses on the literature surrounding hypothalamic regulation of energy and glucose homeostasis and discusses how dysregulation of this system may contribute to obesity and T2DM.
Collapse
|
6
|
Hansen HH, Hansen G, Tang-Christensen M, Larsen PJ, Axel AMD, Raben A, Mikkelsen JD. The novel triple monoamine reuptake inhibitor tesofensine induces sustained weight loss and improves glycemic control in the diet-induced obese rat: comparison to sibutramine and rimonabant. Eur J Pharmacol 2010; 636:88-95. [PMID: 20385125 DOI: 10.1016/j.ejphar.2010.03.026] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2009] [Revised: 02/22/2010] [Accepted: 03/14/2010] [Indexed: 11/19/2022]
Abstract
Tesofensine, a novel triple monoamine reuptake inhibitor, produces a significant weight loss in humans. The present study aimed at characterizing the weight-reducing effects of tesofensine in a rat model of diet-induced obesity. Sibutramine and rimonabant were used as reference comparators. Compared to baseline, long-term treatment with tesofensine (28 days, 1.0 or 2.5mg/kg, p.o.) resulted in a significant, dose-dependent and sustained weight loss of 5.7 and 9.9%, respectively. Sibutramine (7.5mg/kg, p.o.) treatment caused a sustained weight loss of 7.6%, whereas the employed dose of rimonabant (10mg/kg, p.o.) only produced a transient weight reduction. While all compounds exhibited a significant inhibitory effect on food intake which gradually wore off, the hypophagic effect of tesofensine was longer lasting than sibutramine and rimonabant. In contrast to tesofensine, the body weight of pair-fed rats returned to baseline at the end of the study, which may indicate that tesofensine stimulated energy expenditure. The differential efficacy on weight reduction was also reflected in lowered body fat depots, as tesofensine and sibutramine most efficiently reduced abdominal and subcutaneous fat mass which was paralleled by reduced plasma lipid levels. In an oral glucose tolerance test, only tesofensine significantly suppressed the plasma insulin response below the level that could be obtained by paired feeding, indicating that tesofensine further improved glycemic control. In conclusion, the robust weight loss with long-term tesofensine treatment is likely due to a combined synergistic effect of appetite suppression and increased energy expenditure.
Collapse
Affiliation(s)
- Henrik H Hansen
- NeuroSearch A/S, Pederstrupvej 93, DK-2750 Ballerup, Copenhagen, Denmark.
| | | | | | | | | | | | | |
Collapse
|
7
|
Jewett DC, Hahn TW, Smith TR, Fiksdal BL, Wiebelhaus JM, Dunbar AR, Filtz CR, Novinska NL, Levine AS. Effects of sibutramine and rimonabant in rats trained to discriminate between 22- and 2-h food deprivation. Psychopharmacology (Berl) 2009; 203:453-9. [PMID: 18854986 DOI: 10.1007/s00213-008-1350-1] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/02/2008] [Accepted: 09/20/2008] [Indexed: 11/24/2022]
Abstract
OBJECTIVE The objective of the study was to evaluate whether sibutramine and rimonabant, drugs that decrease food intake in human and non-human animals, affect the discriminative stimulus effects associated with acute food deprivation ("hunger"). MATERIALS AND METHODS Rats were trained to discriminate between 22- and 2-h food deprivation in a two-lever choice procedure. After rats acquired the discrimination, subjects were food-restricted for 22 h and administered with sibutramine (0.32-10 mg/kg, p.o.) or rimonabant (0.32-10 mg/kg, s.c.) before a generalization test session. RESULTS Sibutramine (3.2 mg/kg) produced significant decreases in 22-h deprivation-appropriate responding, response rates (resulting in lever pressing rates similar to those following 2-h food deprivation), and food intake measured 1 h after the generalization test. A larger sibutramine dose eliminated responding and significantly reduced food intake. Rimonabant did not alter the discriminative stimulus effects of 22-h food deprivation, but rimonabant did significantly reduce both response rates and food intake. CONCLUSION Sibutramine appears to decrease food intake by reducing hunger sensations associated with food deprivation. In contrast, rimonabant does not alter the discrimination of acute food deprivation. The use of food-deprivation discrimination techniques may be useful in identifying the role of specific neuroactive compounds in eating stimulated by a sense of hunger and may aid in medication development for more effective treatments for obesity and other eating-related conditions.
Collapse
Affiliation(s)
- David C Jewett
- Department of Psychology, University of Wisconsin-Eau Claire, Eau Claire, WI, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Tallett A, Blundell J, Rodgers R. Sibutramine-induced anorexia: Potent, dose-dependent and behaviourally-selective profile in male rats. Behav Brain Res 2009; 198:359-65. [DOI: 10.1016/j.bbr.2008.11.011] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2008] [Revised: 11/06/2008] [Accepted: 11/09/2008] [Indexed: 01/08/2023]
|
9
|
Antal-Zimanyi I, Bruce MA, Leboulluec KL, Iben LG, Mattson GK, McGovern RT, Hogan JB, Leahy CL, Flowers SC, Stanley JA, Ortiz AA, Poindexter GS. Pharmacological characterization and appetite suppressive properties of BMS-193885, a novel and selective neuropeptide Y(1) receptor antagonist. Eur J Pharmacol 2008; 590:224-32. [PMID: 18573246 DOI: 10.1016/j.ejphar.2008.06.032] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2007] [Revised: 05/28/2008] [Accepted: 06/06/2008] [Indexed: 10/22/2022]
Abstract
Treatment of obesity is still a large unmet medical need. Neuropeptide Y is the most potent orexigenic peptide in the animal kingdom. Its five cloned G-protein couple receptors are all implicated in the regulation of energy homeostasis evidenced by overexpression or deletion of neuropeptide Y or its receptors. Neuropeptide Y most likely exerts its orexigenic activity via the neuropeptide Y(1) and neuropeptide Y(5) receptors, although the involvement of the neuropeptide Y(2) and neuropeptide Y(4) receptors are also gaining importance. The lack of potent, selective, and brain penetrable pharmacologic agents at these receptors made our understanding of the modulation of food intake by neuropeptide Y-ergic agents elusive. BMS-193885 (1,4-dihydro-[3-[[[[3-[4-(3-methoxyphenyl)-1-piperidinyl]propyl]amino] carbonyl]amino]phenyl]-2,6-dimethyl-3,5-pyridinedicarboxylic acid, dimethyl ester) is a potent and selective neuropeptide Y(1) receptor antagonist. BMS-193885 has 3.3 nM affinity at the neuropeptide Y(1) receptor, acting competitively at the neuropeptide Y binding site. BMS-193885 increased the K(d) of [(125)I]PeptideYY from 0.35 nM to 0.65 nM without changing the B(max) (0.16 pmol/mg of protein) in SK-N-MC cells that endogenously express the neuropeptide Y(1) receptor. It is also found to be a full antagonist with an apparent K(b) of 4.5 nM measured by reversal of forskolin (FK)-stimulated inhibition of cAMP production by neuropeptide Y. Pharmacological profiling showed that BMS-193885 has no appreciable affinity at the other neuropeptide Y receptors, and is also 200-fold less potent at the alpha(2) adrenergic receptor. Testing the compound in a panel of 70 G-protein coupled receptors and ion channels resulted in at least 200-fold or greater selectivity, with the exception of the sigma(1) receptor, where the selectivity was 100-fold. When administered intracerebroventricularly or directly into the paraventricular nucleus of the hypothalamus, it blocked neuropeptide Y-induced food intake in rats. Intraperitoneal administration of BMS-193885 (10 mg/kg) also reduced one-hour neuropeptide Y-induced food intake in satiated rats, as well as spontaneous overnight food consumption. Chronic administration of BMS-193885 (10 mg/kg) i.p. for 44 days significantly reduced food intake and the rate of body weight gain compared to vehicle treated control without developing tolerance or affecting water intake. These results provide supporting evidence that BMS-193885 reduces food intake and body weight via inhibition of the central neuropeptide Y(1) receptor. BMS-193885 has no significant effect of locomotor activity up to 20 mg/kg dose after 1 h of treatment. It also showed no activity in the elevated plus maze when tested after i.p. and i.c.v. administration, indicating that reduction of food intake is unrelated to anxious behavior. BMS-193885 has good systemic bioavailability and brain penetration, but lacks oral bioavailability. The compound had no serious cardiovascular adverse effect in rats and dogs up to 30 and 10 mg/kg dose, respectively, when dosed intravenously. These data demonstrate that BMS-193885 is a potent, selective, brain penetrant Y(1) receptor antagonist that reduces food intake and body weight in animal models of obesity both after acute and chronic administration. Taken together the data suggest that a potent and selective neuropeptide Y(1) receptor antagonist might be an efficacious treatment for obesity in humans.
Collapse
Affiliation(s)
- Ildiko Antal-Zimanyi
- Bristol-Myers Squibb, Neuroscience Research, 5 Research Pkwy, Wallingford, CT, USA.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Atkinson TJ. Central and peripheral neuroendocrine peptides and signalling in appetite regulation: considerations for obesity pharmacotherapy. Obes Rev 2008; 9:108-20. [PMID: 18257752 DOI: 10.1111/j.1467-789x.2007.00412.x] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Abstract
Appetite and satiety are mediated by complex neuroendocrine signalling pathways involving over 40 hormones, neuropeptides, enzymes, other chemical messengers and their receptors. Research efforts continue to expand understanding of the role of signalling molecules between central hypothalamic nuclei and peripheral enteroendocrine cells; and discoveries of novel networks and messengers provide new biological insights on how to manipulate appetite-satiety pathways. Despite the vast array of peptides that are potentially useful for anti-obesity drug development, only four classes of agents are approved: (i) catecholamine stimulants; (ii) serotonin and noradrenaline reuptake inhibitors; (iii) lipase inhibitors; and (iv) more recently cannabinoid-1 receptor antagonists. Clinical effects of these drugs confer modest improvements, and side effects negatively impact long-term treatment course. This paper suggests single target pharmacological interventions are possibly hampered by the myriad of alternate orexigenic peptidic signals that drive hyperphagia, hence a multiple target model or combination treatment approach is proposed to offer greater therapeutic potential in modulating appetite and managing weight.
Collapse
|
11
|
Xu J, Dz Chen J. Effects of sibutramine on gastric emptying, intestinal motility and rectal tone in dogs. Dig Dis Sci 2008; 53:155-62. [PMID: 17510801 DOI: 10.1007/s10620-007-9837-x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/10/2006] [Accepted: 03/30/2007] [Indexed: 12/19/2022]
Abstract
The aim of this study was to evaluate the effects of sibutramine on gastric emptying, small-bowel contractions, rectal tone and compliance, and gastrointestinal myoelectrical activity. The study was performed in 14 dogs. It was composed of three separate experiments: gastric emptying of liquids and gastrointestinal slow waves; small-bowel contractions; and rectal tone and rectal compliance. Each experiment included two sessions: a control session and a treatment session with sibutramine (5 mg/kg orally) administrated 2 h before the study. Sibutramine significantly accelerated liquid gastric emptying at 75 and 90 min after the meal but did not alter gastrointestinal slow waves. Gastric emptying at 75 and 90 min was 61.42 +/- 7.71 and 66.32 +/- 7.67% in the control session, and increased to 71.27 +/- 5.14 and 75.93 +/- 5.29% in the session with sibutramine (p < 0.05, vs. control). Sibutramine significantly inhibited postprandial small-bowel contractions. Sibutramine did not alter the rectal tone, but significantly increased rectal compliance. Sibutramine accelerates gastric emptying of liquids but inhibits small-bowel contractions. These findings suggest the peripheral mechanisms of sibutramine in reducing food intake and causing weight loss in obesity patients.
Collapse
Affiliation(s)
- Junying Xu
- Division of Gastroenterology, University of Texas Medical Branch, Galveston, TX 77555-0632, USA
| | | |
Collapse
|
12
|
Shrestha S, Bhattarai BR, Lee KH, Cho H. Mono- and disalicylic acid derivatives: PTP1B inhibitors as potential anti-obesity drugs. Bioorg Med Chem 2007; 15:6535-48. [PMID: 17692525 DOI: 10.1016/j.bmc.2007.07.010] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2007] [Revised: 07/07/2007] [Accepted: 07/10/2007] [Indexed: 01/04/2023]
Abstract
A series of compounds containing one or two salicylic acid moieties were synthesized, and their efficacy to inhibit the phosphohydrolase activity of PTP1B examined. Some of the methylenedisalicylic acid derivatives were potent inhibitors of PTP1B. Of those derivatives, 3c exhibited about a 14-fold selectivity against TC-PTP, and this compound was tested in a mouse model for its efficacy to prevent diet-induced obesity. It effectively suppressed the increases in body weight and adipose mass, without any noticeable toxic effect. The compound also prevented increases in the plasma triglyceride, cholesterol, and nonesterified fatty acid concentrations; thus, expanding its therapeutic potential to other related metabolic diseases, such as hyperlipidemia and hypercholesterolemia.
Collapse
Affiliation(s)
- Suja Shrestha
- Department of Chemistry and Institute of Molecular Cell Biology, College of Natural Sciences, Inha University, Incheon 402-751, Republic of Korea
| | | | | | | |
Collapse
|
13
|
Fernstrom JD, Choi S. The development of tolerance to drugs that suppress food intake. Pharmacol Ther 2007; 117:105-22. [PMID: 17950459 DOI: 10.1016/j.pharmthera.2007.09.001] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2007] [Accepted: 09/04/2007] [Indexed: 10/22/2022]
Abstract
Appetite suppressants have been available as weight-reducing aids for over 50 years. The first discovered was amphetamine, which was potent, but possessed undesirable side effects (it is a stimulant and elevates blood pressure). Subsequently, a variety of appetite drugs was developed, all structurally related to amphetamine, but mostly lacking unwanted side effects. Until recently, fenfluramine (FEN) was the most widely used; presently, sibutramine is the most commonly used appetite suppressant. While these appetite suppressants are effective at reducing hunger and food intake when given as a single dose or for short periods of time, their effectiveness diminishes when administered chronically. The biological mechanisms underlying this tolerance have not been carefully studied, but many possibilities have been identified, including the down-regulation in brain of neurotransmitter receptors that might mediate the action of these drugs and adaptive responses of the appetite control circuitry in brain. To date, however, few studies have examined these possibilities in any detail. This article focuses on the question of why appetite suppressants lose efficacy, when given chronically, because this issue is important to the development of the next generation of appetite suppressants. Chronic efficacy should be an issue studied relatively early in the drug development process. This issue is of particular relevance, since obesity treatment is now recognized as a long-term, not a short-term, process. If appetite suppressants are to become a more important tool in obesity treatment, agents that do not lose efficacy when administered for extended periods of time must be identified.
Collapse
Affiliation(s)
- John D Fernstrom
- Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA 15213, United States.
| | | |
Collapse
|
14
|
Xu J, Chen JDZ. Peripheral mechanisms of sibutramine involving proximal gastric motility in dogs. Obesity (Silver Spring) 2006; 14:1363-70. [PMID: 16988078 DOI: 10.1038/oby.2006.154] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
OBJECTIVE Sibutramine, a serotonin-norepinephrine uptake inhibitor, has been used for treating obesity. However, its possible mechanisms involving gastric motility have not been reported. The aim of this study was to evaluate the effects of sibutramine on gastric accommodation and antral motility. RESEARCH METHODS AND PROCEDURES The study was performed in seven dogs with a stomach cannula and composed of two separate experiments: antral contractions and gastric tone. Each experiment included two sessions on 2 separate days in a randomized order: a control session and a treatment session with sibutramine (5 mg/kg per os) administrated 2 hours before the study. RESULTS Sibutramine significantly increased fasting gastric tone; the gastric volume in the fasting state at baseline was 103.8 +/- 12.3 mL and significantly decreased to 35.3 +/- 16.0 mL with sibutramine (p = 0.0075). Sibutramine also impaired gastric accommodation. The average postprandial gastric volume was 472.1 +/- 16.7 mL in the control session and reduced to 302.2 +/- 53.6 mL with sibutramine (p = 0.013). The average postprandial increase in gastric volume during the 60-minute postprandial period with sibutramine was significantly lower than the corresponding values in the control session: 266.8 +/- 46.1 vs. 393.9 +/- 15.3 mL (p = 0.03). Sibutramine had no effects on postprandial antral contractions. DISCUSSION Sibutramine increases gastric tone and impairs gastric accommodation to an orally ingested meal. The inhibitory effect of sibutramine on gastric accommodation may partially explain the reduced food intake with sibutramine in patients with obesity.
Collapse
Affiliation(s)
- Junying Xu
- Division of Gastroenterology, University of Texas Medical Branch, Galveston, Texas, USA
| | | |
Collapse
|
15
|
Fisas A, Codony X, Romero G, Dordal A, Giraldo J, Mercé R, Holenz J, Heal D, Buschmann H, Pauwels PJ. Chronic 5-HT6 receptor modulation by E-6837 induces hypophagia and sustained weight loss in diet-induced obese rats. Br J Pharmacol 2006; 148:973-83. [PMID: 16783408 PMCID: PMC1751931 DOI: 10.1038/sj.bjp.0706807] [Citation(s) in RCA: 71] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2006] [Revised: 04/27/2006] [Accepted: 05/05/2006] [Indexed: 11/09/2022] Open
Abstract
E-6837 is a novel, selective and high-affinity 5-HT(6) receptor ligand (pK(i): 9.13) which in vitro demonstrates partial agonism at a presumably silent rat 5-HT(6) receptor and full agonism at a constitutively active human 5-HT(6) receptor by monitoring the cAMP signaling pathway.The effects of chronic treatment with E-6837 were determined in diet-induced obese (DIO)-rats on changes in body weight, food and water intake, plasma indices of comorbid risk factors, and weight regain on compound withdrawal. The centrally acting antiobesity drug, sibutramine, was used as the reference comparator. Sustained body weight loss and decreased cumulative food intake of DIO-rats was observed with E-6837 (30 mg kg(-1), p.o., twice a day) during the 4-week treatment period. The onset of the E-6837 effect on body weight was slower than that of sibutramine (5 mg kg(-1), p.o.), while its maximal effect was greater, that is -15.7 versus -11.0%.E-6837-induced weight loss was exclusively mediated by a decrease (31.7%) in fat mass, with a concomitant reduction (49.6%) in plasma leptin. Reduced obesity was also reflected in improved glycemic control. Although weight regain occurred after withdrawal from either compound, the body weights after E-6837 (-6.6%) remained lower than after sibutramine (-3.8%) indicating that the greater efficacy of the former did not result in profound rebound hyperphagia/weight gain. These results show that the 5-HT(6) receptor partial agonist, E-6837, is a promising new approach to the management of obesity with the potential to produce greater sustained weight loss than sibutramine.
Collapse
Affiliation(s)
- Angels Fisas
- Laboratorios Dr. Esteve S.A., Av. Mare de Déu de Montserrat 221, 08041 Barcelona, Spain
| | - Xavier Codony
- Laboratorios Dr. Esteve S.A., Av. Mare de Déu de Montserrat 221, 08041 Barcelona, Spain
| | - Gonzalo Romero
- Laboratorios Dr. Esteve S.A., Av. Mare de Déu de Montserrat 221, 08041 Barcelona, Spain
| | - Alberto Dordal
- Laboratorios Dr. Esteve S.A., Av. Mare de Déu de Montserrat 221, 08041 Barcelona, Spain
| | - Jesus Giraldo
- Grup Biomatemàtic de Recerca, Institut de Neurociències and Unitat de Bioestadística, Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain
| | - Ramon Mercé
- Laboratorios Dr. Esteve S.A., Av. Mare de Déu de Montserrat 221, 08041 Barcelona, Spain
| | - Jörg Holenz
- Laboratorios Dr. Esteve S.A., Av. Mare de Déu de Montserrat 221, 08041 Barcelona, Spain
| | - David Heal
- RenaSci Consultancy Ltd, Biocity, Nottingham, NG1 1GF
| | - Helmut Buschmann
- Laboratorios Dr. Esteve S.A., Av. Mare de Déu de Montserrat 221, 08041 Barcelona, Spain
| | - Petrus Johan Pauwels
- Laboratorios Dr. Esteve S.A., Av. Mare de Déu de Montserrat 221, 08041 Barcelona, Spain
| |
Collapse
|
16
|
Vrang N, Madsen AN, Tang-Christensen M, Hansen G, Larsen PJ. PYY(3-36) reduces food intake and body weight and improves insulin sensitivity in rodent models of diet-induced obesity. Am J Physiol Regul Integr Comp Physiol 2006; 291:R367-75. [PMID: 16914421 DOI: 10.1152/ajpregu.00726.2005] [Citation(s) in RCA: 98] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
The gut hormone peptide YY (PYY) was recently proposed to comprise an endogenous satiety factor. We have studied acute anorectic functions of PYY(3-36) in mice and rats, as well as metabolic effects of chronic PYY(3-36) administration to diet-induced obese (DIO) mice and rats. A single intraperitoneal injection of PYY(3-36) inhibited food intake in mice, but not in rats. We next investigated the effects of increasing doses (100, 300, and 1,000 microg.kg-1.day-1) of PYY(3-36) administered subcutaneously via osmotic minipumps on food intake and body weight in DIO C57BL/6J mice. Whereas only the highest dose (1,000 microg.kg-1.day-1) of PYY(3-36) significantly reduced food intake over the first 3 days, body weight gain was dose dependently reduced, and on day 28 the group treated with 1,000 microg.kg-1.day-1 PYY(3-36) weighed approximately 10% less than the vehicle-treated group. Mesenteric, epididymal, retroperitoneal, and inguinal fat pad weight was dose dependently reduced. Subcutaneous administration of PYY(3-36) (250 and 1,000 microg.kg-1.day-1) for 28 days reduced body weight and improved glycemic control in glucose-intolerant DIO rats. Neither 250 nor 1,000 microg/kg PYY(3-36) elicited a conditioned taste aversion in male rats.
Collapse
Affiliation(s)
- Niels Vrang
- Rheoscience, Glerupvej 2, 2610 Rødovre, Denmark.
| | | | | | | | | |
Collapse
|
17
|
Abstract
Sequencing of the human genome has yielded thousands of potential drug targets. The difficulty now is in determining which targets have real therapeutic value and should be the focus of a drug discovery effort. The available evidence suggests that knockout technology can be used prospectively to identify targets that are amenable to drug development for the treatment of a variety of diseases. This review compares the knockout phenotypes of 21 potential obesity targets with the effects of therapeutics designed for those targets on rodents and, when data were available, on humans. The phenotypes of obesity target knockouts model the effects seen when therapeutics designed for those obesity targets are delivered to rodents; of the 21 obesity targets reviewed, 16 showed a correspondence between knockout phenotype and drug effect in mice and/or rats. This suggests that, at least in terms of evaluating obesity targets, it is rare for compensatory developmental changes caused by the gene knockout to prevent detection of the relevant phenotype. In the majority of cases, the knockout phenotypes also modelled the effects seen when the relevant therapeutics were delivered to humans. Thus, it seems rational to use mouse knockout technology prospectively to identify genes that regulate body fat in vivo, and then to develop anti-obesity therapeutics by targeting the human protein products of these genes. Ultimately, the value of using this approach to identify novel targets for human anti-obesity therapies will be judged by future studies examining the anti-obesity effect, in humans, of the therapeutics that result from this approach.
Collapse
Affiliation(s)
- D R Powell
- Department of Endocrinology, Pharmaceutical Biology, Lexicon Genetics Incorporated, 8800 Technology Forest Place, The Woodlands, TX 77381-1160, USA.
| |
Collapse
|
18
|
Wargent E, Sennitt MV, Stocker C, Mayes AE, Brown L, O'Dowd J, Wang S, Einerhand AWC, Mohede I, Arch JRS, Cawthorne MA. Prolonged treatment of genetically obese mice with conjugated linoleic acid improves glucose tolerance and lowers plasma insulin concentration: possible involvement of PPAR activation. Lipids Health Dis 2005; 4:3. [PMID: 15642120 PMCID: PMC546236 DOI: 10.1186/1476-511x-4-3] [Citation(s) in RCA: 50] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2004] [Accepted: 01/10/2005] [Indexed: 12/13/2022] Open
Abstract
Background Studies in rodents and some studies in humans have shown that conjugated linoleic acid (CLA), especially its trans-10, cis-12 isomer, reduces body fat content. However, some but not all studies in mice and humans (though none in rats) have found that CLA promotes insulin resistance. The molecular mechanisms responsible for these effects are unclear, and there are conflicting reports on the effects of CLA on peroxisomal proliferator-activated receptor-γ (PPARγ) activation and expression. We have conducted three experiments with CLA in obese mice over three weeks, and one over eleven weeks. We have also investigated the effects of CLA isomers in PPARγ and PPARα reporter gene assays. Results Inclusion of CLA or CLA enriched with its trans-10, cis-12 isomer in the diet of female genetically obese (lepob/lepob) mice for up to eleven weeks reduced body weight gain and white fat pad weight. After two weeks, in contrast to beneficial effects obtained with the PPARγ agonist rosiglitazone, CLA or CLA enriched with its trans-10, cis-12 isomer raised fasting blood glucose and plasma insulin concentrations, and exacerbated glucose tolerance. After 10 weeks, however, CLA had beneficial effects on glucose and insulin concentrations. At this time, CLA had no effect on the plasma TNFα concentration, but it markedly reduced the plasma adiponectin concentration. CLA and CLA enriched with either isomer raised the plasma triglyceride concentration during the first three weeks, but not subsequently. CLA enriched with its trans-10, cis-12 isomer, but not with its cis-9, trans-11 isomer, stimulated PPARγ-mediated reporter gene activity; both isomers stimulated PPARα-mediated reporter gene activity. Conclusions CLA initially decreased but subsequently increased insulin sensitivity in lepob/lepob mice. Activation of both PPARγ and PPARα may contribute to the improvement in insulin sensitivity. In the short term, however, another mechanism, activated primarily by trans-10, cis-12-CLA, which probably leads to reduced adipocyte number and consequently reduced plasma adiponectin concentration, may decrease insulin sensitivity.
Collapse
Affiliation(s)
- Ed Wargent
- Clore Laboratory for Life Sciences, University of Buckingham, Buckingham, MK18 1EG, UK
| | - Matthew V Sennitt
- Clore Laboratory for Life Sciences, University of Buckingham, Buckingham, MK18 1EG, UK
| | - Claire Stocker
- Clore Laboratory for Life Sciences, University of Buckingham, Buckingham, MK18 1EG, UK
| | - Andrew E Mayes
- Biosciences division, Unilever Research, Colworth Laboratory, Sharnbrook, Bedfordshire, MK44 1LQ, UK
| | - Louise Brown
- Biosciences division, Unilever Research, Colworth Laboratory, Sharnbrook, Bedfordshire, MK44 1LQ, UK
| | - Jacqueline O'Dowd
- Clore Laboratory for Life Sciences, University of Buckingham, Buckingham, MK18 1EG, UK
| | - Steven Wang
- Clore Laboratory for Life Sciences, University of Buckingham, Buckingham, MK18 1EG, UK
| | | | - Inge Mohede
- Lipid Nutrition, Loders Croklaan BV, PO Box 4, 1520 AA Wormerveer, The Netherlands
| | - Jonathan RS Arch
- Clore Laboratory for Life Sciences, University of Buckingham, Buckingham, MK18 1EG, UK
| | - Michael A Cawthorne
- Clore Laboratory for Life Sciences, University of Buckingham, Buckingham, MK18 1EG, UK
| |
Collapse
|
19
|
Hsieh YS, Hsu JD, Yang SF, Kuo DY. Immunohistochemical and genomic evidence for the involvement of hypothalamic neuropeptide Y (NPY) in phenylpropranolamine-mediated appetite suppression. Peptides 2004; 25:2155-61. [PMID: 15572205 DOI: 10.1016/j.peptides.2004.08.015] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/10/2004] [Revised: 08/14/2004] [Accepted: 08/20/2004] [Indexed: 11/29/2022]
Abstract
Phenylpropanolamine (PPA) is an appetite suppressant. The mechanism for the anorectic effect of PPA has been attributed to its action on the site of hypothalamic paraventriculum. Neuropeptide Y (NPY) is an appetite stimulant that is widely distributed in the site of hypothalamus. It is not clear whether hypothalamic NPY is involved in the anorectic action of PPA. This study was aimed to investigate the mechanism underlying the involvement of NPY gene in the anorectic action of PPA. Results revealed that PPA treatment in rats could decrease both NPY content and mRNA level in the hypothalamus. In addition, the expression of NPY immunoreactivity following PPA treatment was decreased in areas of hypothalamic arcuate nucleus, paraventricular nucleus and periventricular area using immunohistochemical staining, suggesting an involvement of NPYergic pathway in the action of PPA anorexia. Our results provided immunohistochemical and genomic evidence to suggest that PPA might reduce feeding by altering NPY gene expression.
Collapse
Affiliation(s)
- Yih-Shou Hsieh
- Institute of Biochemistry, Chung Shan Medical University, Taichung City 402, Taiwan, ROC
| | | | | | | |
Collapse
|
20
|
Kim DM, Yoon SJ, Ahn CW, Cha BS, Lim SK, Kim KR, Lee HC, Huh KB. Sibutramine improves fat distribution and insulin resistance, and increases serum adiponectin levels in Korean obese nondiabetic premenopausal women. Diabetes Res Clin Pract 2004; 66 Suppl 1:S139-44. [PMID: 15563965 DOI: 10.1016/j.diabres.2003.12.008] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/11/2003] [Accepted: 12/09/2003] [Indexed: 11/13/2022]
Abstract
The aim of this study was to evaluate the effects of sibutramine on body composition and fat distribution, insulin resistance, and serum adiponectin levels in obese women. A total of 28 obese, premenopausal women (mean age, 34.5 +/- 13.7 years; BMI, 31.00 +/- 4.10 kg/m2) was studied before and after 12-week-course of sibutramine (10mg/day). Sibutramine treatment reduced body mass index (P < 0.05) and total body fat (P < 0.05). Abdominal subcutaneous and visceral fat areas (ASFA and AVFA) and mid-thigh low density muscle areas (LDMA) measured by computed-tomography decreased significantly (all, P < 0.05). Insulin resistance (IR) calculated from the homeostasis model assessment (HOMA) method decreased (P < 0.05) and serum adiponectin levels increased significantly (P < 0.05). In our sequential data, the changes of fasting serum insulin levels and the HOMA-IR scores, serum free fatty acids and triglyceride levels, serum adiponectin levels and the mid-thigh LDMA preceded significant changes of body weight, total body fat, and abdominal fat distribution, suggesting sibutramine might improve insulin sensitivity directly by alterations of fatty acid metabolism or secondarily by increasing serum adiponectin levels. Conclusively, sibutramine improved fat distribution and insulin resistance, and increased serum adiponectin levels in Korean obese nondiabetic premenopausal women.
Collapse
Affiliation(s)
- D M Kim
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Yongdong Severance Hospital, College of Medicine, Yonsei University, 146-92 Dogok-Dong, Kangnam-Ku, Seoul, Republic of Korea
| | | | | | | | | | | | | | | |
Collapse
|
21
|
Abstract
Sibutramine, a serotonin-noradrenaline reuptake inhibitor (SNRI), has been shown to be a safe and effective weight-loss drug. The purpose of the present study was to examine whether sibutramine has an effect on macronutrient selection in both female and male rats in addition to total food intake. Wistar rats of both sexes were divided into three groups, and each group was offered a different set of three sensorily contrasting macronutrient-specific diets, each set including carbohydrate-, protein-, and fat-rich diets. Sibutramine (10 mg/kg) was shown to consistently decrease carbohydrate and fat intake at all data points regardless of gender and diet. Intake of carbohydrate differed between male and female rats at 2 h post administration with 2.5 and 5 mg/kg of sibutramine. The effect of sibutramine on protein intake was diet- and gender-specific. All doses of sibutramine decreased total food intake regardless of gender and diet group beginning at 6 h post administration. In conclusion, sibutramine affected macronutrient selection and emphasis on dietary recommendations, as well as appropriate dosage according to gender should be considered during therapy.
Collapse
Affiliation(s)
- M LeBlanc
- School of Dietetics and Human Nutrition, McGill University-Macdonald Campus, 21111 Lakeshore Road, Ste-Anne-de-Bellevue, QC, Canada H9X 3V9
| | | |
Collapse
|
22
|
Casado A, Rodríguez VM, Portillo MP, Macarulla MT, Abecia LC, Echevarría E, Casis L. Sibutramine decreases body weight gain and increases energy expenditure in obese Zucker rats without changes in NPY and orexins. Nutr Neurosci 2003; 6:103-11. [PMID: 12722985 DOI: 10.1080/1028415031000094264] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
The aim of the present work was to describe the effects of sibutramine on body weight and adiposity and to establish the potential involvement of neuropeptide Y (NPY) and orexins in the anorectic action of this drug. Male obese Zucker rats were daily administered with sibutramine (10 mg/kg, intraperitoneal) for two weeks. Carcass composition was assessed using the official methods of the Association of Official Analytical Chemists. Total body oxygen consumption was measured daily for 60 min before sibutramine or saline injection and for 30 min (from 60 to 90 min) after drug or saline injection. Hypothalamic arcuate and paraventricular nuclei, and the lateral hypothalamic area were immunostained for NPY, orexin A and orexin B. Commercial kits were used for serum determinations. Reductions in body weight and adipose tissue weights were observed after sibutramine treatment in obese Zucker rats. No changes in NPY immunostaining in the arcuate and paraventricular nuclei were found. Orexin A and orexin B immunostaining was not modified in the lateral hypothalamic area in treated rats. The reduction in body weight and adiposity induced by sibutramine was achieved by both a reduction in food intake and an increase in energy expenditure. NPY and orexins do not seem to be involved in the anorectic effect of sibutramine.
Collapse
Affiliation(s)
- A Casado
- Department of Physiology, Faculty of Pharmacy, University of the Basque Country, Paseo de la Universidad 7, 01006 Vitoria, Spain
| | | | | | | | | | | | | |
Collapse
|
23
|
Saracíbar G, Casado A, Rodríguez VM, Portillo MP, Macarulla MT, Abecia LC, Echevarría E, Casis L. Nefazodone alters NPY immunostaining in rat arcuate-paraventricular projection without changes in food intake and body weight. Nutr Neurosci 2002; 5:353-8. [PMID: 12385598 DOI: 10.1080/1028415021000033820] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
Nefazodone is an antidepressant drug that inhibits serotonin and noradrenaline reuptake. The aim of the present work was to study the effects of nefazodone on food intake, body weight, adiposity and hypothalamic NPY immunostaining in rats. For this purpose, male Sprague-Dawley rats (3-month-old) were administered with nefazodone (20 mg/kg; i.p) daily for two weeks. The control group was given 0.9% NaCl solution. Hypothalamic arcuate, paraventricular, periventricular, supraoptic and suprachiasmatic nuclei and the lateral hypothalamic area were immunostained for NPY. Chronic nefazodone administration in rats did not modify food intake, body weight and adipose depot size (subcutaneous, perirenal and epididymal white adipose tissues, and interscapular brown adipose tissue). However, a significant decrease in paraventricular NPY immunostaining was found in the nefazodone group compared with the control group. No changes in other hypothalamic regions such as arcuate, periventricular, supraoptic and suprachiasmatic nuclei, and lateral and medial preoptic areas were observed. Because nefazodone is an alpha1-adrenoceptor antagonist, it can be proposed that the expected decrease in food intake after nefazodone administration, due to its effects on NPY arcuate-paraventricular projection, could be masked by the opposite orexigenic effect of alpha1-adrenoceptor blockade.
Collapse
Affiliation(s)
- G Saracíbar
- Department of Physiology, School of Pharmacy, University of the Basque Country, Vitoria, Spain
| | | | | | | | | | | | | | | |
Collapse
|
24
|
Turnbull AV, Ellershaw L, Masters DJ, Birtles S, Boyer S, Carroll D, Clarkson P, Loxham SJG, McAulay P, Teague JL, Foote KM, Pease JE, Block MH. Selective antagonism of the NPY Y5 receptor does not have a major effect on feeding in rats. Diabetes 2002; 51:2441-9. [PMID: 12145156 DOI: 10.2337/diabetes.51.8.2441] [Citation(s) in RCA: 63] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Neuropeptide Y (NPY) is thought to play a key role in stimulating feeding, thus making NPY receptors attractive appetite suppressant drug targets for treating obesity. Because the orexigenic effects of NPY have been ascribed to actions at the NPY Y5 receptor, we have determined the role of this receptor in feeding in rats, using a small molecule antagonist of this receptor. NPY5RA-972 is a selective and potent (<10 nmol/l) NPY Y5 receptor antagonist. This compound is central nervous system (CNS) penetrant, and an oral dose of 10 mg/kg NPY5RA-972 to rats produced concentrations in cerebrospinal fluid that greatly exceeded the in vitro IC(50) (inhibitory concentration 50%). Indeed, at doses to rats as low as 1 mg/kg, NPY5RA-972 inhibited feeding induced by intracerebroventricular (ICV) administration of a selective NPY Y5 agonist ([cPP(1-7),NPY(19-23),Ala(31),Aib(32),Gln(34)]-hPP). However, in the dose range 1-10 mg/kg, NPY5RA-972 had no significant effect on food intake in Wistar rats induced to feed by either ICV NPY or 24 h fasting or in free-feeding Wistar or obese Zucker rats. Chronic administration of NPY5RA-972 (10 mg/kg twice daily) had no effect on food intake or body weight in either free-feeding Wistar rats or dietary obese rats. These data indicate that NPY5RA-972 is a potent, selective, orally active, and CNS-penetrant antagonist of the NPY Y5 receptor that prevents feeding driven by activation of this receptor. The data obtained with this antagonist indicate that the NPY Y5 receptor is not a major regulator of feeding in the rat.
Collapse
Affiliation(s)
- Andrew V Turnbull
- Cardiovascular and Gastrointestinal Discovery Department, AstraZeneca, Mereside, Alderley Park, Macclesfield, UK.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|